Compare MTD & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTD | INSM |
|---|---|---|
| Founded | 1991 | 1988 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8B | 30.1B |
| IPO Year | 1997 | 2000 |
| Metric | MTD | INSM |
|---|---|---|
| Price | $1,231.53 | $143.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | ★ $1,444.17 | $201.17 |
| AVG Volume (30 Days) | 126.6K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.88 | N/A |
| EPS | ★ 42.05 | N/A |
| Revenue | ★ $4,026,399,000.00 | N/A |
| Revenue This Year | $6.07 | $182.31 |
| Revenue Next Year | $4.75 | $65.19 |
| P/E Ratio | $31.31 | ★ N/A |
| Revenue Growth | ★ 3.98 | N/A |
| 52 Week Low | $1,029.23 | $63.81 |
| 52 Week High | $1,525.17 | $212.75 |
| Indicator | MTD | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 43.04 |
| Support Level | $1,161.00 | $142.99 |
| Resistance Level | $1,290.85 | $149.08 |
| Average True Range (ATR) | 34.25 | 4.92 |
| MACD | -3.00 | -1.53 |
| Stochastic Oscillator | 2.79 | 15.41 |
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.